IDEXX Laboratories stock (US45168D1046): Q1 revenue rises 14.3%

IDEXX Laboratories reported first-quarter 2026 earnings on May 5, with EPS and revenue both ahead of estimates and full-year guidance lifted.

IDEXX Laboratories reported first-quarter 2026 earnings on May 5, 2026, with adjusted EPS of $3.47 and revenue of $1.14 billion, both above consensus, according to MarketBeat as of 05/05/2026. The company also raised its fiscal 2026 outlook, giving US investors a fresh update on a veterinary diagnostics business that trades on Nasdaq under ticker IDXX.

As of: 18.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories
• Sector/industry: Veterinary diagnostics and animal health
• Home exchange/listing venue: Nasdaq (IDXX)
• Trading currency: U.S. dollars
• Core markets: United States, Europe and other international animal-health markets

IDEXX Laboratories: core business model

IDEXX Laboratories develops diagnostic instruments, consumables and software used by veterinarians, reference laboratories and livestock producers. The business is built around recurring testing volumes, installed analyzers and recurring consumable use, which can smooth revenue compared with more cyclical product-only models. For US investors, that makes the company relevant not only as a healthcare name but also as a recurring-revenue diagnostics story.

The latest quarterly report showed that the model remains active: revenue climbed 14.3% year over year to $1.14 billion in the March quarter, while EPS of $3.47 topped the market estimate cited by MarketBeat. The company also said it expects fiscal 2026 revenue of $4.7 billion to $4.8 billion, which suggests management sees continued demand across companion-animal and other diagnostic channels, according to the same May 5 update.

Main revenue and product drivers for IDEXX Laboratories

The main revenue engine remains veterinary diagnostics, where instruments, test kits and recurring consumables feed one another. That structure matters because higher testing volumes can increase reagent and cartridge usage, while a larger installed base supports future recurring demand. The company’s software and workflow tools also help anchor customer relationships, giving the business a broader platform than single-product healthcare peers.

Company results often reflect trends in pet care spending, clinic throughput and the pace of diagnostic adoption. In the May 5 earnings update, IDEXX said fiscal 2026 EPS guidance now stands at $14.45 to $14.90, compared with consensus around $14.52, while revenue guidance of $4.7 billion to $4.8 billion framed expectations for the current year. For investors tracking healthcare exposure beyond drugmakers, that combination of recurring diagnostics and installed-base economics remains the key point.

Why IDEXX Laboratories matters for US investors

IDEXX has a direct US-market footprint through its Nasdaq listing and its exposure to American pet ownership, veterinary clinic spending and broader healthcare services demand. The stock is also watched as a quality-growth name because earnings updates can quickly affect sentiment when reported growth is above or below expectations. The May 5 release was one such moment, with both earnings and revenue ahead of consensus.

MarketBeat reported the stock closed at $528.79 on May 15, 2026, after the earnings update and guidance change, giving market participants a recent reference point for how investors were pricing the company’s growth profile. The company’s scale and international reach also make it relevant for US portfolios seeking exposure to animal health rather than human pharmaceuticals alone.

Conclusion

IDEXX Laboratories entered mid-May with a fresh earnings update that showed faster sales growth and an EPS beat, while management also nudged full-year expectations higher. The company’s recurring diagnostics model remains the central investment feature, especially for US investors looking for healthcare-linked growth outside traditional drug development. The key question from here is whether clinic demand and consumables growth can sustain the momentum implied by the latest guidance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.